BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

San Mateo, Calif., United States:   5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression

READ MORE

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

San Mateo, Calif., United States:   Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with

READ MORE